Remote Monitoring of Patient Reported Outcomes to Improve the Efficacy of the Acute Phase Radiotherapy Review Process
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Feb 15, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how using mobile phone apps to collect information about side effects can help improve the care of patients undergoing radiation therapy (RT) for breast and prostate cancer. The idea is that when patients report their symptoms through the app, their healthcare providers can better understand their needs and decide when they should be seen for additional care. This could lead to better management of side effects, which in turn could improve patients' quality of life and overall health.
To be eligible for this trial, participants must have a clinical diagnosis of breast or prostate cancer and be starting radiation therapy at the Princess Margaret Cancer Centre. They should be able to use the app to report their symptoms in either English or French. During the trial, participants can expect to regularly share their experiences through the app, which will help their healthcare team know if they need to meet more often or if they can wait longer between visits. Overall, this trial aims to make the treatment process more efficient and supportive for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of breast or prostate cancer
- • About to receive a course of radical or adjuvant radiation therapy as an outpatient at Princess Margaret Cancer Centre
- • Able to enter PRO responses into the mobile app in English or French
- Exclusion Criteria:
- • Significant comorbidities that would render the patient not suitable for remote monitoring
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported